Burcon NutraScience Corp.

  • WKN: 157793
  • ISIN: CA1208311029
  • Land: Kanada

Nachricht vom 10.09.2018 | 08:13

Burcon NutraScience Corp.: Burcon Announces Results of Shareholder Meeting

DGAP-News: Burcon NutraScience Corp. / Key word(s): AGM/EGM

10.09.2018 / 08:13
The issuer is solely responsible for the content of this announcement.


Burcon Announces Results of Shareholder Meeting

Vancouver, British Columbia, September 7, 2018 - Burcon NutraScience Corporation (TSX: BU) a leader in functional, renewable plant-based proteins, is pleased to announce the results from its 2018 annual and special meeting of shareholders (the "Meeting") held on September 6, 2018. All of the seven nominees set out in Burcon's management proxy circular dated July 19, 2018 proposed by management for election to the board of directors at the Meeting were elected to the board. Each director elected will hold office until the conclusion of the next annual meeting of shareholders of Burcon or until his or her successor is elected or appointed, unless his or her office is earlier vacated in accordance with Burcon's by-laws or with the provisions of the Business Corporations Act (Yukon).

The results of the voting on the election of the directors are as follows:

Director Nominee Votes For % Votes For Votes Withheld % Votes Withheld Non Votes
Allan Yap 17,540,085 90.99 1,736,650 9.01 1,690,462
Rosanna Chau 18,162,682 94.22 1,114,053 5.78 1,690,462
David Lorne John Tyrrell 18,157,678 94.19 1,119,057 5.81 1,690,462
Alan Chan 18,018,388 93.47 1,258,347 6.53 1,690,462
J. Douglas Gilpin 18,157,678 94.19 1,119,057 5.81 1,690,462
Peter H. Kappel 18,157,678 94.19 1,119,057 5.81 1,690,462
David Ju 18,003,788 93.40 1,272,947 6.60 1,690,462
 

Shareholders of the Corporation also approved all other items of business brought forward at the Meeting.

About Burcon NutraScience Corporation

Burcon is a leader in developing technologies for the production of valuable plant-sourced ingredients for use in food, nutrition, wellness and supplement products. The company has developed a portfolio of composition, application, and process patents originating from a core protein extraction and purification technology. Burcon's CLARISOY(R) soy protein is the clear choice for dairy protein replacement, with equivalent protein content to dairy, CLARISOY(R) offers excellent solubility and exceptionally clean flavor at any pH; Peazazz(R) is a uniquely soluble and clean-tasting pea protein; and Puratein(R), Supertein(R) and Nutratein(R) are canola protein isolates with unique functional and nutritional attributes. Burcon is also conducting research to develop extraction and isolation processes for the production of purified cannabinoid extracts from cannabis and other organic source materials. For more information about the company, visit www.burcon.ca.


The TSX has not reviewed and does not accept responsibility for the adequacy of the content of the information contained herein. This press release contains forward-looking statements or forward-looking information within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and applicable Canadian securities legislation. Forward-looking statements or forward-looking information involve risks, uncertainties and other factors that could cause actual results, performances, prospects and opportunities to differ materially from those expressed or implied by such forward-looking statements. Forward- looking statements or forward-looking information can be identified by words such as "anticipate," "intend," "plan," "goal," "project," "estimate," "expect," "believe", "future," "likely," "may," "should," "could", "will" and similar references to future periods. All statements other than statements of historical fact included in this release are forward-looking statements, including, without limitation, statements regarding expectations, intentions and plans contained in this press release. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements or information. Important factors that could cause actual results to differ materially from Burcon's plans and expectations include the actual results of business negotiations, marketing activities, adverse general economic, market or business conditions, regulatory changes and other risks and factors detailed herein and from time to time in the filings made by Burcon with securities regulators and stock exchanges, including in the section entitled "Risk Factors" in Burcon's annual information form dated June 18, 2018 filed with the Canadian securities administrators on www.sedar.com. Any forward-looking statement or information only speaks as of the date on which it was made and, except as may be required by applicable securities laws, Burcon disclaims any intent or obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. Although Burcon believes that the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance, and accordingly, investors should not rely on such statements.

CLARISOY is a trademark of Archer Daniels Midland Company.

Media & Industry Contact:
Paul Lam
Manager, Business Development
Burcon NutraScience Corporation
Tel (604) 733-0896, Toll-free (888) 408-7960
plam@burcon.ca www.burcon.ca



10.09.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


show this

GBC-Fokusbox

HELMA Eigenheimbau: Klarer Kauf

Die HELMA Eigenheimbau hat mit dem Zugang weiterer Ferienimmobilienprojekte das potenzielle Umsatzvolumen um 150 Mio. € gesteigert. Ohnehin verfügt die Gesellschaft über einen umfangreichen Grundstücksbestand für das Bauträgergeschäft, womit in den kommenden Geschäftsjahren Umsätze in Höhe von über 1,4 Mrd. € realisiert werden könnten. Damit dürften unsere Schätzungen, in denen wir ein nachhaltiges Überschreiten der Umsatzmarke von 300 Mio. € annehmen, gut unterfüttert sein. Bei einem Kursziel von 65,00 € ist die HELMA-Aktie ein klarer Kauf.

News im Fokus

Munich Re beschließt Aktienrückkauf

26. Februar 2020, 13:17

Aktuelle Research-Studie

Schloss Wachenheim AG

Original-Research: Schloss Wachenheim AG (von First Berlin Equity Research GmbH): Kaufen

27. Februar 2020